Sagimet Biosciences Inc. (SGMT)

NASDAQ: SGMT · Real-Time Price · USD
9.83
+1.47 (17.58%)
At close: Jun 24, 2025, 4:00 PM
9.86
+0.03 (0.31%)
After-hours: Jun 24, 2025, 7:56 PM EDT
17.58%
Market Cap 316.48M
Revenue (ttm) n/a
Net Income (ttm) -57.11M
Shares Out 32.20M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,838,972
Open 8.37
Previous Close 8.36
Day's Range 8.37 - 10.43
52-Week Range 1.73 - 10.43
Beta n/a
Analysts Strong Buy
Price Target 23.17 (+135.71%)
Earnings Date Aug 13, 2025

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2023
Employees 14
Stock Exchange NASDAQ
Ticker Symbol SGMT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price forecast is $23.17, which is an increase of 135.71% from the latest price.

Price Target
$23.17
(135.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

15 days ago - GlobeNewsWire

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FA...

20 days ago - Seeking Alpha

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to seve...

20 days ago - GlobeNewsWire

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...

4 weeks ago - GlobeNewsWire

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 Phase 1 clinical trial to eva...

6 weeks ago - GlobeNewsWire

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation...

3 months ago - GlobeNewsWire

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...

3 months ago - GlobeNewsWire

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Denifanstat is SGMT's leading FASN inhibitor for MASH. It has shown strong Phase 2b results and earned the FDA Breakthrough Therapy designation. SGMT also has a diversified pipeline on acne, solid tum...

3 months ago - Seeking Alpha

Sagimet: More Than Just A MASH Drug Development Biotech

Sagimet Biosciences Inc.'s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024....

7 months ago - Seeking Alpha

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China , Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc....

8 months ago - PRNewsWire

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's u...

8 months ago - Seeking Alpha

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis - - Results support advancement of denifanstat ...

9 months ago - GlobeNewsWire

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to initiate Phase 3 program for denifanstat by the end of 2024 SAN MATEO, Calif...

9 months ago - GlobeNewsWire

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

9 months ago - GlobeNewsWire

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

SAN MATEO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitor...

10 months ago - GlobeNewsWire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors...

11 months ago - GlobeNewsWire

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences is progressing with Denifanstat research targeting MASH, acne, and cancer with promising Phase 2b trial results. Denifanstat is progressing toward Phase 3 trials, with positive res...

11 months ago - Seeking Alpha

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET

1 year ago - GlobeNewsWire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance f...

1 year ago - GlobeNewsWire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet's topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH Dr. Scott Friedman to present unmet need in MASH...

1 year ago - GlobeNewsWire

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024

1 year ago - GlobeNewsWire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

SAN MATEO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors ...

1 year ago - GlobeNewsWire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors ...

1 year ago - GlobeNewsWire

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences is a clinical-stage biopharmaceutical company researching a cure for metabolic dysfunction-related diseases by inhibiting fatty acid synthase. Revenue generated so far comes from l...

1 year ago - Seeking Alpha

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 Sagimet annou...

1 year ago - GlobeNewsWire